Recombinant Mouse Tumor necrosis factor receptor superfamily member 5 (Cd40)

What is CD40 and what is its significance in immunology research?

CD40 is a 48 kD type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor (TNFR) superfamily. It serves as a critical costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen-presenting cells. CD40 plays essential roles in multiple immunological processes including Ig isotype switching, dendritic cell maturation, and the activation, differentiation and proliferation of B cells. It also interacts with TNFR2 and functions in the regulation of signal transduction pathways . The biological significance of CD40 extends beyond normal immune function, making it an important research target for understanding immune disorders, cancer immunotherapy approaches, and neurodegenerative conditions like Alzheimer's disease .

How does recombinant mouse CD40 differ from native mouse CD40?

Recombinant mouse CD40 is typically produced as a fusion protein (often with an Fc tag) in expression systems such as NS0 cells to ensure proper folding and post-translational modifications. While the core protein structure remains consistent with native CD40, recombinant versions may include additional elements like fusion tags that can affect protein solubility, half-life, and in some cases, biological activity. High-quality recombinant mouse CD40 preparations maintain >90% purity as determined by SDS-PAGE and silver staining, with endotoxin levels below 0.1 EU/μg to ensure experimental reliability . The biological activity of recombinant mouse CD40 is specifically validated through functional assays measuring its ability to inhibit rmCD40 ligand-induced B cell proliferation, with typical ED50 values ranging from 0.1-0.3 μg/ml in the presence of 100 ng/ml recombinant mouse CD40 ligand .

What is the CD40-CD154 signaling axis and why is it important?

The CD40-CD154 (CD40L) signaling axis represents a crucial costimulatory pathway in the immune system. CD40 interacts with its ligand CD154 (a 39 kD protein) to trigger multiple downstream signaling events that are essential for adaptive immunity. This interaction is particularly important for:

• B cell activation, proliferation, and differentiation

• Antibody class switching

• Germinal center formation

• Dendritic cell maturation and activation

• T cell-dependent humoral responses

Therapeutically, blocking the interaction of CD40 with CD154 has emerged as an important objective for preventing and/or improving both autoimmune diseases and transplant rejection . Additionally, the CD40-CD154 interaction has been identified as essential for amyloid-beta-induced microglial activation, thus playing a significant role in Alzheimer's disease pathogenesis .

How can researchers track CD40 signaling during germinal center development?

Tracking CD40 signaling during germinal center (GC) development requires sophisticated molecular approaches that assess pathway activation. Research has revealed that despite the requirement of CD40 signaling for GC formation, the signaling itself is not consistently active throughout GC development. Investigators can track CD40 signaling through:

• Gene expression signature analysis: By inducing CD40 signaling in transformed GC B cells in vitro and identifying a CD40 gene expression signature using DNA microarray analysis. This signature can then be investigated in the gene expression profiles of normal B cells .

• Tracking nuclear factor-κB (NF-κB) translocation: Upon CD40 stimulation, NF-κB transcription factors translocate from the cytoplasm to the nucleus. Immunohistochemical or imaging approaches that detect this translocation can serve as visual indicators of active CD40 signaling .

• Continuous binary scoring methods: These quantitative approaches measure the extent to which genes that are up-regulated or down-regulated in CD40-untreated cells compared to treated cells show the same differential expression trend across different cell populations. The scoring system incorporates normalized differences in average expression between cell types, providing statistical significance to the observed patterns .

Research using these approaches has surprisingly revealed that the CD40 signature is present in pre- and post-GC B cells (naive and memory) but not in GC B cells themselves, suggesting that GC expansion occurs largely in the absence of CD40 signaling, which may act primarily in the initial and final stages of the GC reaction .

What are the key considerations when designing experiments to measure CD40-mediated B cell activation?

When designing experiments to measure CD40-mediated B cell activation, researchers should consider:

• Appropriate positive and negative controls: Include CD40 ligand stimulation as positive control and isotype-matched controls for antibody experiments.

• Dose-response relationships: The biological activity of mouse CD40 shows a specific dose-dependent relationship, with ED50 values typically in the range of 0.1-0.3 μg/ml when in the presence of 100 ng/ml recombinant mouse CD40 ligand .

• Readout selection: Various parameters can indicate B cell activation:

  • Proliferation assays (thymidine incorporation or flow cytometry-based)

  • Surface activation marker expression (CD69, CD80, CD86)

  • Cytokine/chemokine production

  • Antibody class switching

• Temporal considerations: CD40 signaling effects vary over time:

  • Early activation markers appear within hours

  • Proliferation peaks at 48-72 hours

  • Antibody production and class switching require longer timeframes

• Cell purity and viability: Ensure B cells are properly isolated and maintain high viability (>90%) prior to experiments.

• Endotoxin contamination: Recombinant proteins should have endotoxin levels <0.1 EU/μg to prevent non-specific activation .

What are the optimal conditions for using recombinant mouse CD40 in in vitro research models?

The optimal conditions for using recombinant mouse CD40 in in vitro research depend on the specific experimental goals. For inhibition studies of CD40-CD154 interactions, researchers should consider:

Storage and Handling:

• Store lyophilized protein at -20°C to -80°C

• Reconstitute in sterile buffer without carrier protein for maximum flexibility

• Allow protein to equilibrate to room temperature before reconstitution

• Once reconstituted, prepare aliquots to avoid freeze-thaw cycles

Experimental Parameters:

• Concentration range: For inhibition studies, typically 0.1-0.3 μg/ml of recombinant mouse CD40 effectively inhibits B cell proliferation induced by 100 ng/ml recombinant mouse CD40 ligand

• Medium composition: Serum can affect protein activity; consider testing both serum-containing and serum-free conditions

• Incubation time: Varies based on experimental endpoint (24-96 hours)

• Temperature: Standard cell culture conditions (37°C, 5% CO2)

Quality Control:

• Verify protein activity using established bioassays

• Confirm low endotoxin levels (<0.1 EU/μg) to prevent non-specific immune activation

• Check purity (>90% by SDS-PAGE with silver stain)

How can researchers effectively measure the biological activity of recombinant mouse CD40?

The biological activity of recombinant mouse CD40 can be reliably measured through several complementary approaches:

• B Cell Proliferation Inhibition Assay: The standard method determines CD40's ability to inhibit recombinant mouse CD40 ligand-induced B cell proliferation. The expected ED50 for this effect typically ranges from 0.1-0.3 μg/ml when tested in the presence of 100 ng/ml recombinant mouse CD40 ligand .

• Competitive Binding Assays: These assess the ability of recombinant CD40 to compete with cell-surface CD40 for binding to CD154.

• Downstream Signaling Analysis: Measuring activation of NF-κB pathway components or other signaling molecules like JNK and p38 MAPK after CD40-CD154 interaction.

• Flow Cytometry-Based Competition Assays: Using fluorescently labeled CD154 to quantify the inhibition of binding to cell-surface CD40 in the presence of recombinant mouse CD40.

• Reporter Cell Lines: Engineered cell lines expressing CD40-responsive elements driving reporter gene expression can provide a quantitative readout of functional activity.

How should researchers interpret contradictory findings in CD40 signaling studies?

Contradictory findings in CD40 signaling studies are not uncommon and require careful analysis. When encountering contradictory results, researchers should consider:

• Cell Type and Context Specificity: CD40 signaling pathways and outcomes differ significantly between cell types. For instance, the CD40 signaling patterns observed in B cells differ from those in dendritic cells or monocytes. Research has shown that CD40 gene expression signatures are present in naive and memory B cells but notably absent in germinal center B cells, highlighting the context-dependent nature of CD40 signaling .

• Experimental Model Variations: Different mouse strains, primary cells versus cell lines, and in vitro versus in vivo studies can yield different results. The presence or absence of cofactors in the experimental system can significantly impact CD40 signaling outcomes.

• Temporal Dynamics: CD40 signaling is not static but changes over time. Studies on germinal center development suggest that CD40 signaling may be critical during the initial and final stages of the germinal center reaction rather than during the expansion phase .

• Reagent Considerations: Different forms of recombinant CD40 (soluble versus membrane-bound, tagged versus untagged) and various anti-CD40 antibodies (agonistic versus antagonistic) can produce divergent results.

• Pathway Crosstalk: CD40 signaling interacts with multiple other pathways. For example, CD40 interacts with TNFR2 in the regulation of signal transduction , which may lead to different experimental outcomes depending on the status of these interacting pathways.

To resolve contradictions, researchers should implement:

• Stringent biological replicates and statistical analysis

• Multiple complementary techniques to examine the same biological question

• Careful consideration of positive and negative controls

• Detailed reporting of experimental conditions

• Use of gene expression patterns and NF-κB localization as objective markers of CD40 pathway activation

What are the key biomarkers for evaluating CD40-targeted therapeutic interventions?

When evaluating CD40-targeted therapeutic interventions, researchers should monitor several key biomarkers that reflect pathway modulation and therapeutic efficacy:

• B Cell Dynamics:

  • Quantitative changes in peripheral blood B cell counts

  • Alterations in CD21 expression, which shows reduced expression following CD40 pathway modulation

  • B cell activation markers (CD80, CD86)

  • Antibody production and class switching

• NK Cell Parameters:

  • Changes in NK cell numbers, which typically show transient reductions

  • Increased CD54 expression, observed at higher doses of CD40-targeted agents

• Cytokine/Chemokine Profile:

  • MIP-1β and IL12 plasma concentrations, which rise after effective CD40 modulation

  • TNF-α, IL-6, and other inflammatory cytokines

• NF-κB Pathway Activation:

  • Nuclear translocation of NF-κB subunits in target cells

  • Expression of NF-κB-dependent genes

• Safety Biomarkers:

  • Liver transaminase levels, as elevation may indicate dose-limiting toxicity

  • Inflammatory markers (CRP, ESR)

  • Monitoring for cytokine release syndrome

In clinical applications, doses of 200 mg × 4 (approximately 2.1-3.3 mg/kg based on patient body weight) of agonistic anti-CD40 antibodies have been established as the maximum tolerated dose, with liver transaminase elevations occurring at higher doses (240 mg) . At therapeutic doses, trough levels above 25 μg/mL have been documented before treatment, providing a pharmacokinetic biomarker for monitoring .

How is recombinant mouse CD40 being utilized in immunotherapy research?

Recombinant mouse CD40 and CD40-targeting agents are being extensively investigated in immunotherapy research across several innovative approaches:

• Cancer Immunotherapy Applications: CD40 has emerged as a promising target for cancer immunotherapy . Researchers are using mouse models with recombinant CD40 to:

  • Enhance dendritic cell-mediated tumor antigen presentation

  • Convert immunosuppressive tumor microenvironments to immunostimulatory ones

  • Combine CD40 agonism with immune checkpoint inhibitors for synergistic effects

  • Study mechanisms of resistance to CD40-based immunotherapies

• Alternative Approaches to CD40-CD154 Blockade: Since monoclonal antibodies blocking CD154 in human clinical trials resulted in unanticipated vascular complications, there is growing interest in therapeutic antagonist monoclonal antibodies specific for CD40 . Particularly valuable are those that do not inhibit CD40 signaling via physical competition with CD154, but rather through alternative mechanisms.

• Germinal Center Reaction Modulation: Research reveals that CD40 signaling may be critical only during the initial and final stages of the germinal center reaction . This finding is leading to more precise temporal targeting of CD40 in conditions requiring modulation of antibody responses.

• Dosing Strategy Optimization: Clinical studies with agonistic anti-CD40 antibodies (like ChiLob7/4) have established biologically effective dose ranges and identified dose-dependent effects including B cell depletion and NK cell modulation . These insights are informing more refined dosing strategies in both preclinical mouse models and clinical applications.

Evidence from clinical studies demonstrates that properly dosed CD40-targeting agents can achieve disease stabilization in treatment-resistant conditions, with some patients maintaining stability for extended periods (median 6 months, longest 37 months) .

What roles does CD40 signaling play in neurodegenerative disease models?

CD40 signaling has emerged as a significant contributor to neuroinflammatory processes in neurodegenerative diseases, particularly in Alzheimer's disease. Research using mouse models has revealed several key mechanisms:

• Amyloid-beta-Induced Microglial Activation: The interaction between CD40 and its ligand (CD154) has been identified as essential for amyloid-beta-induced microglial activation, playing a significant role in Alzheimer's disease pathogenesis . This discovery positions CD40 signaling as a potential therapeutic target for modulating neuroinflammation.

• Neuroinflammatory Cascade Regulation: CD40 signaling influences the production of pro-inflammatory cytokines and reactive oxygen species by microglia and astrocytes in response to various pathological triggers. Mouse models with CD40 modulation show altered inflammatory profiles in the central nervous system.

• Blood-Brain Barrier Integrity: CD40-CD154 interactions affect blood-brain barrier permeability and leukocyte infiltration into the CNS, contributing to disease progression in models of multiple sclerosis and other neuroinflammatory conditions.

• Synaptic Plasticity and Neuronal Survival: Emerging research suggests that CD40 signaling may directly or indirectly impact synaptic function and neuronal survival, with potential implications for cognitive decline in neurodegenerative disorders.

These findings have stimulated research into CD40-targeted interventions for neurodegenerative conditions, with approaches including:

• Selective CD40-CD154 interaction inhibitors with CNS penetrance

• Cell-specific targeting of CD40 signaling in microglia versus peripheral immune cells

• Temporal modulation of CD40 signaling at different disease stages

• Combination therapies targeting both amyloid/tau pathology and CD40-mediated neuroinflammation